Today: 30 June 2026
Exxon Mobil stock dips from 52-week high as oil slides; what to watch before XOM earnings

Exxon Mobil stock dips from 52-week high as oil slides; what to watch before XOM earnings

New York, Jan 22, 2026, 12:37 EST — Regular session

  • Exxon Mobil shares edged down roughly 0.2% in midday trading, following a close at a 52-week peak just yesterday.
  • Oil dropped roughly 2% earlier as U.S. crude inventories increased in the latest weekly government report.
  • Traders have their eyes on the upcoming EIA report due Jan. 28 and Exxon’s quarterly earnings set for Jan. 30.

Shares of Exxon Mobil Corp (XOM) slipped 0.2% to $133.34 in midday New York trading on Thursday, pulling back after hitting a 52-week closing high just a day earlier.

This shift is significant as Exxon has been acting like a macro proxy lately — a mix of oil exposure and headline risk. Following a strong two-day rally, investors are waiting on cues from crude ahead of earnings season kicking off.

By 10:14 a.m. ET, U.S. stocks edged up following President Donald Trump’s softened tariff stance on Europe. Meanwhile, November’s PCE inflation climbed 2.8% year-over-year, a bit above expectations. The PCE index remains the Fed’s favored inflation measure.

Oil dipped earlier Thursday, with Brent futures dropping $1.01 to $64.23 a barrel. U.S. WTI lost 96 cents, trading at $59.66 by 11:26 a.m. ET. Ole Hansen, Saxo Bank’s chief commodity analyst, pointed to a “deflation of risk premium related to the Greenland debacle.” IG’s Tony Sycamore added that prices should stay near $60 a barrel. Reuters

Data from the U.S. Energy Information Administration revealed that commercial crude oil inventories increased by 3.6 million barrels last week, reaching 426.0 million barrels. Gasoline stocks surged by 6.0 million barrels, while distillate inventories climbed 3.3 million barrels.

Exxon surged 2.41% on Wednesday, closing at $133.61, marking its third consecutive rise and hitting a fresh 52-week peak, according to MarketWatch data. Trading volume reached roughly 18.8 million shares, surpassing the 50-day average of 16.4 million.

The rally took off once Wall Street bounced sharply after Trump eased off threats to impose tariffs over the Greenland dispute. Jason Pride, Glenmede’s chief of investment strategy and research, noted, “The economic impact is whether we all start imposing tariffs on each other.” Reuters

Oil stocks showed uneven moves Thursday. Chevron edged higher by 0.4%, while ConocoPhillips slipped around 0.7% in midday trading.

The situation could shift quickly if crude continues to slide or Exxon’s report shows that weaker prices are hitting cash flow. Exxon warned earlier this month that lower crude prices might slash fourth-quarter upstream earnings by somewhere between $800 million and $1.2 billion. Here, “upstream” refers to its oil-and-gas production segment. Reuters

Exxon announced in a filing that it plans to release its fourth-quarter 2025 results around 5:30 a.m. Central time on Friday, Jan. 30.

Traders are also eyeing the weekly U.S. petroleum report set for Jan. 28—a key figure that can swiftly sway crude prices when inventory levels climb. Exxon’s next major date to watch is Jan. 30.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors.

Stock Market Today

  • SELLAS Life Sciences (NASDAQ:SLS) Drops 7.77% After 8-K Filing Ahead of REGAL Data
    June 30, 2026, 10:28 AM EDT. SELLAS Life Sciences shares dropped 7.77% to $14.25 on Tuesday after an 8-K showing senior management agreements and as the market waits for Phase 3 REGAL data on galinpepimut-S in AML. The study is approaching a milestone with 78 of 80 survival events, making some investors cautious. The stock recently hit a 52-week high of $15.67, but resistance is holding there with support at the 20-day simple moving average around $8.87. Technicals are flashing overbought with the RSI at 85.19, which could mean sharper pullbacks. SELLAS works on cancer therapies including GPS and CDK9 drugs, tying its shares to updates around leadership moves and clinical trials.
UPL share price slips as Advanta IPO papers hit SEBI: what the filing reveals
Previous Story

UPL share price slips as Advanta IPO papers hit SEBI: what the filing reveals

Accenture stock price rises as Palantir-backed “sovereign AI” data-center deal grabs focus
Next Story

Accenture stock price rises as Palantir-backed “sovereign AI” data-center deal grabs focus

Go toTop